TMC435-TiDP16-C113: A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of TMC435
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to investigate the effect of moderate and severe hepatic
impairment on the pharmacokinetics of TMC435. Pharmacokinetics means how the drug is absorbed
into the bloodstream, distributed in the body and eliminated from the body. In addition, the
short-term safety and tolerability of TMC435 in participants with hepatic impairment will be
determined. The results of this study will guide dose recommendations for TMC435 in patients
with impaired liver function.